Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial

CONCLUSION: There were no clinically meaningful adverse changes in routine laboratory parameters attributable to treatment with dupilumab + TCS. Changes in platelet counts and lactate dehydrogenase levels likely reflect reduced inflammation. These results confirm similar findings in adults and adolescents, and suggest that there is no need for routine laboratory monitoring of children aged 6-11 years treated with dupilumab + TCS for severe AD.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03345914. Does treatment with dupilumab require routine laboratory monitoring in 6- to 11-year-old children with severe atopic dermatitis? (MP4 180482 kb).PMID:34462864 | DOI:10.1007/s40272-021-00459-x

Source: Paediatric Drugs - August 31, 2021 Category: Pediatrics Authors: Amy S Paller Andreas Wollenberg Elaine Siegfried Diamant Tha çi Michael J Cork Peter D Arkwright Melinda Gooderham Xian Sun John T O'Malley Faisal A Khokhar Jignesh Vakil Ashish Bansal Karli Rosner Brad Shumel Noah A Levit Source Type: research